Clinical trials: CNS Infection
Encephalitis, Japanese B
Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
Japanese encephalitis (JE) is the main cause of viral encephalitis in many countries of Asia including Thailand. Estimated annual mortality ranges from10,000-15,000 deaths, while the total number of clinical cases is about…
- Trial name
- JE0153 (NCT01408537)
- Testing
- JEVAC
- Where
- Thailand
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Depression, Stress, Psychological
Rural Dementia Caregiver Project
Rural caregivers face challenges of geographic isolation and lower health care access and quality. Many rural dementia caregivers experience serious health consequences due to caregiving responsibilities that can limit their…
- Conditions
- Depression, Stress, Psychological, Self Efficacy, Loneliness
- Trial name
- NCT04428112
- Testing
- Building Better Caregivers Workshop, Attention Control
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Japanese Encephalitis, Measles
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT01188343
- Testing
- Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
- Where
- 3 sites in Taiwan
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Physical Disability
A Community Wellness Program for Adults Living With Long-term Physical Disability
For people living with long-term physical disabilities, such as spinal cord injury or multiple sclerosis, middle-age (45-64) is a period of great vulnerability for losses in function and participation.
- Trial name
- EW-D (NCT03653390)
- Testing
- EnhanceWellness for Disability (EW-D), Wellness Education
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- University of Washington
Multiple Sclerosis, Relapsing Forms
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT01585766
- Testing
- MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, MEDI-551 100 MG-IV
- Where
- 16 sites in United States, Poland and 2 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Stroke (CVA) or TIA, Diabetes
Risk Factors, Costs, and Impacts of ED Boarding
The goal of this observational study is to learn about the risk factors, costs, and operational impacts of emergency department boarding (patients admitted to the hospital but remaining in the emergency department awaiting…
- Conditions
- Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
- Trial name
- NCT07532564
- Where
- United States
- Volunteers
- 30,486 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Primary Objective: To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00831311
- Testing
- DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- Where
- Argentina
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease, Meningococcal Meningitis
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
- Trial name
- NCT01214837
- Testing
- MenACWY-CRM, Routine Vaccines
- Where
- 40 sites in United States, Canada
- Volunteers
- 751 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
This study is designed to evaluate the immunogenicity and the safety of a quadrivalent vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
- Trial name
- NCT01274897
- Testing
- Novartis MenACWY-CRM
- Where
- 8 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
HIV Disease
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
In this study we will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the brain…
- Trial name
- NCT01929759
- Testing
- Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Japanese Encephalitis
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
- Trial name
- NCT00595309
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
HIV Infections
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals.
- Trial name
- NCT00987948
- Testing
- maraviroc (Selzentry)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Malaria, Cerebral
Treating Brain Swelling in Pediatric Cerebral Malaria
This study evaluates the effectiveness of two interventions in Malawian children with cerebral malaria at high risk of death. One-third of the participants will receive treatment as usual, one-third will receive treatment as…
- Trial name
- TBS (NCT03300648)
- Testing
- Mechanical ventilation, Hypertonic saline
- Where
- Malawi
- Volunteers
- 57 people
- Sponsor
- Michigan State University
Poliomyelitis
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
This study is designed to evaluate the safety and immunogenicity of two novel type 2 oral poliovirus vaccine (nOPV2) candidates (nOPV2 candidate 1 and nOPV2 candidate 2) in adults.
- Trial name
- NCT04544787
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- 2 sites in Belgium
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Meningitis, Meningococcal, Serogroup B
Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.
The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the…
- Trial name
- NCT02305446
- Testing
- Meningococcal (group B) multicomponent recombinant adsorbed vaccine
- Where
- Poland
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Novartis
Diphtheria, Pertussis
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
The purpose of this survey is to collect selected safety data. Primary Objective: To collect selected safety data at 6 months following the 4th dose of the Pentacel® series.
- Conditions
- Diphtheria, Pertussis, Haemophilus Infection, Tetanus
- Trial name
- NCT00772369
- Where
- Canada
- Volunteers
- 3,214 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Poliomyelitis
Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.
- Trial name
- NCT00920439
- Testing
- PoliorixTM
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline